The main features of MultiFLEXA 250 continuous motion capsule filling machine from MG2 are reliability, speed and flexibility. 
The machine is capable of producing 250,000 capsules an hour and also includes the MultiNETT weight control system. 
The MultiFLEXA 250 features two dosing stations of the ‘no capsule – no dosage’ type, which saves on products and avoids their dispersion in the processing area and the environment. The stations are suitable for any oral solid form and relevant combinations. 
The capsule handling and product dosing area is completely separate from the technical zone, which includes transmission elements and lubrication systems. 
To optimise the product flow, the MultiFLEXA 250 can be integrated with automatic loading systems for capsules and products, as well as systems to sort, clean and distribute filled capsules at the outfeed.
A containment version, which ensures the insulation of the filling zone, and a fully automated Wash in Place version are also offered. 
To control and guarantee the production quality, MG2 says the MultiFLEXA 250 can be equipped with MultiNETT, a 100% weight control system integrated to the machine that checks in process the net weight of each dosed capsule. It can also check product microdosages and the different components in dosage combinations.
MultiNETT allows the quantity of dosed product to be measured accurately, because the body is kept in a fixed position inside the sensor for quite a long time. The system employs the capacitive tomography to guarantee accuracy and precision, regardless of variables such as the position or the quantity of product inside the capsule. 
The MultiNETT technology can be applied to production machines, as well as to those used in laboratories. 
MG2 equips other machines with the MultiNETT system, including the Microdose (semi-automatic filling unit for laboratories), Planeta (capsule filler for medium productions) and Labby or FlexaLAB (machines suitable for r&d laboratories, clinical trials, small batches and special productions).
                    
                
MultiFLEXA 250 offers speed and flexibility
Continuous motion capsule filling machine is equipped with the MultiNETT weight control system
You may also like
Trending Articles
You may also like
                                                            Manufacturing
                                                        
                                
                                                                            
                                                                    
                                
                    Codexis and Nitto Denko Avecia Collaborate to Advance Enzymatic Manufacturing of Therapeutic siRNA
The evaluation agreement will see Nitto Denko Avecia assess Codexis’s ECO Synthesis Manufacturing Platform — an enzyme-catalysed, scalable alternative to traditional solid-phase oligonucleotide synthesis aimed at transforming siRNA production
                                                                    
                                
                            
                        
                                                            Manufacturing
                                                        
                                
                                                                            
                                                                    
                                
                    Lilly partners with NVIDIA to build pharma’s most powerful AI supercomputer for faster drug discovery
Eli Lilly has joined forces with NVIDIA to create the world’s most powerful pharmaceutical supercomputer, designed to accelerate AI-driven medicine discovery and manufacturing — all while running entirely on renewable energy
                                                                    
                                
                            
                        
                                                            Regulatory
                                                        
                                
                                                                            
                                                                    
                                
                    NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date